Search results for " ASTHMA"

showing 10 items of 300 documents

The Arg/Arg polymorphism of the ADRB2 is associated with the severity of allergic asthma

2016

ArginineGenotypeGlycineAdrenergicSettore MED/10 - Malattie Dell'Apparato RespiratorioArginine03 medical and health sciences0302 clinical medicineGenotypemedicineImmunology and AllergyHumans030212 general & internal medicineReceptorAdrenergic beta-2 Receptor AgonistsAsthmaPolymorphism Geneticbusiness.industryHomozygoteAllergic asthmaasthmamedicine.disease030228 respiratory systemImmunologyReceptors Adrenergic beta-2business
researchProduct

Minimal clinically important difference for asthma endpoints: an expert consensus report

2020

Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient's medical management.The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research.A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient repo…

Asthma asthma management minimal clinically important difference end-pointsPulmonary and Respiratory Medicinemedicine.medical_specialtyConsensusDelphi TechniqueEndpoint DeterminationBronchoconstrictionMEDLINEDelphi methodSocio-culturaleSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOminimal clinically important difference; asthma; lung function; biomarkersMCID03 medical and health sciences0302 clinical medicinePredictive Value of TestsmedicineHumansAnti-Asthmatic Agents030212 general & internal medicineDisease management (health)Intensive care medicineLungAsthmalcsh:RC705-779business.industryMinimal clinically important differenceminimal clinically important differenceExpert consensusend-pointslcsh:Diseases of the respiratory systemmedicine.diseaseMCID asthmaAsthmaTreatment Outcome030228 respiratory systemPredictive value of testsEndpoint DeterminationInflammation MediatorsSymptom AssessmentbusinessBiomarkersasthma managementEuropean Respiratory Review
researchProduct

Is diet partly responsible for differences in COVID-19 death rates between and within countries?

2020

Abstract Reported COVID-19 deaths in Germany are relatively low as compared to many European countries. Among the several explanations proposed, an early and large testing of the population was put forward. Most current debates on COVID-19 focus on the differences among countries, but little attention has been given to regional differences and diet. The low-death rate European countries (e.g. Austria, Baltic States, Czech Republic, Finland, Norway, Poland, Slovakia) have used different quarantine and/or confinement times and methods and none have performed as many early tests as Germany. Among other factors that may be significant are the dietary habits. It seems that some foods largely use…

BLOOD-PRESSUREReviewAngiotensin-converting enzyme; Antioxidant; Coronavirus; Diet; Foodlaw.inventionDietary interventions0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases10183 Swiss Institute of Allergy and Asthma ResearchlawMedicine and Health SciencesImmunology and AllergyMedicine030212 general & internal medicine[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseaseseducation.field_of_studyMortality rate3. Good health[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases2723 Immunology and AllergyAntioxidantAngiotensin-converting enzymeAngiotensin-converting enzyme Antioxidant Coronavirus Diet FoodPulmonary and Respiratory Medicine2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)CoronaviruImmunologyPopulation610 Medicine & healthCOVID-19 ; Food ; Angiotensin-converting enzyme ; Diet ; Antioxidant ; CoronavirusSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesEnvironmental healthCOVID-19 ; population ; angiotensin-converting enzymeQuarantineeducation2403 ImmunologyANTIHYPERTENSIVE PEPTIDESbusiness.industryRC581-607GENEPOLYMORPHISMDietCoronavirus[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition030228 respiratory system2740 Pulmonary and Respiratory MedicineFoodImmunologic diseases. Allergybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionRegional differencesCoronavirus Infections
researchProduct

Effects in cigarette smoke stimulated bronchial epithelial cells of a corticosteroid entrapped into nanostructured lipid carriers

2014

Background Nanomedicine studies have showed a great potential for drug delivery into the lung. In this manuscript nanostructured lipid carriers (NLC) containing Fluticasone propionate (FP) were prepared and their biocompatibility and effects in a human bronchial epithelial cell line (16-HBE) stimulated with cigarette smoke extracts (CSE) were tested. Results Biocompatibility studies showed that the NLC did not induce cell necrosis or apoptosis. Moreover, it was confirmed that CSE increased intracellular ROS production and TLR4 expression in bronchial epithelial cells and that FP-loaded NLC were more effective than free drug in modulating these processes. Finally, the nanoparticles increased…

BiocompatibilityCellBiomedical EngineeringMedicine (miscellaneous)Pharmaceutical ScienceApoptosisBronchiBioengineeringChronic obstructive pulmonary disease; Asthma; hronic obstructive pulmonary disease.PharmacologyFluticasone propionatemedicine.disease_causeApplied Microbiology and BiotechnologyNanostructured lipid carriers Corticosteroid Fluticasone propionate Cigarette smoke Airway epithelial cell Chronic obstructive pulmonary disease Asthmachemistry.chemical_compoundAirway epithelial cellmedicineHumansCorticosteroidCells CulturedFluticasoneDrug CarriersNanostructured lipid carriersbusiness.industryResearchChronic obstructive pulmonary diseaseSmokingCigarette smokeEpithelial CellsGlutathioneGlutathioneLipidsAsthmaNanostructuresToll-Like Receptor 4medicine.anatomical_structurechemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoApoptosisDrug deliveryFluticasoneMolecular MedicineReactive Oxygen SpeciesbusinessOxidative stressIntracellularmedicine.drugJournal of Nanobiotechnology
researchProduct

Effects of antioxidants on CSE-induced cell death in human asthmatic primary bronchial epithelial cells

2010

The link between cigarette smoke (CS) and lung inflammation is quite strong, however relatively little is still known on the effects of CS on human bronchial epithelial cells survival during asthma. In this study we focused our attention on the apoptotic effects of CS on healthy (HC) and asthmatic (AS) primary bronchial epithelial cells (PBEC) and on the role of antioxidants to protect epithelial cells from CSE-induced apoptosis. Twenty subjects (10 HC and 10 AS) were recruited for this study and PBEC were obtained by bronchoscopy. PBEC were treated with oxidants (H2O), anti-oxidants (GSH and AA) and cigarette smoke extracts (CSE). Early apoptosis (EA) and necrosis were measured by flow cyt…

Bronchial epithelium; asthma; cigarette smoke; oxidative stressbronchial epithelial cells
researchProduct

Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: A non-inferiority, randomised, double-blind clinical tr…

2015

Summary Background Treatment guidelines for patients with moderate persistent asthma recommend regular therapy with a combination of an inhaled corticosteroid and a longacting β 2 agonist plus as-needed rapid-acting bronchodilators. We investigated whether symptom-driven budesonide and formoterol combination therapy administered as needed would be as effective as regular treatment with this combination plus as-needed symptom-driven terbutaline for patients with moderate asthma. Methods In this non-inferiority randomised clinical trial, we recruited adult patients (18–65 years of age) with stable moderate persistent asthma, according to 2006 Global Initiative for Asthma guidelines. Patients …

BudesonideMalePediatricsKaplan-Meier Estimatelaw.inventionRandomized controlled triallawMedicineOutpatient clinicBudesonide Formoterol Fumarate Drug CombinationAnti-Asthmatic AgentsTreatment Failureeducation.field_of_studyasthma; clinical trialMedicine (all)clinical trialMiddle AgedCombined Modality TherapyBronchodilator AgentsFemalemedicine.drugHumanAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentTerbutalinePopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPlaceboDrug Administration ScheduleNOYoung AdultDouble-Blind MethodAdministration InhalationTerbutalineinhaled corticosteroids LABA asthma clinical trialHumansAnti-Asthmatic AgenteducationBronchodilator AgentPulmonary and Respiratory Medicine; Medicine (all)AsthmaAgedPulmonary and Respiratory Medicine RCT asthmabusiness.industryComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKSmedicine.diseaseAsthmarespiratory tract diseasesFormoterolbusiness
researchProduct

Th17 immunity in children with allergic asthma and rhinitis: a pharmacological approach

2013

Th17 cells and IL-17A play a role in the development and progression of allergic diseases. We analyzed the IL-17A levels in sputum supernatants (Ss), nasal wash (NW) and plasma (P) from Healthy Controls (HC) and children with Asthma/Rhinitis. We tested the expression of IL-17A, RORγ(t) and FOXP3 in peripheral blood T-lymphocytes from intermittent and mild-moderate asthma. The effect of Budesonide and Formoterol was tested "in vitro" on IL-17A, RORγ(t) and FOXP3 expression in cultured T-lymphocytes from mild-moderate asthma/persistent rhinitis patients, and on nasal and bronchial epithelial cells stimulated with NW and Ss from mild-moderate asthma/persistent rhinitis. Further, the effect of …

BudesonideMalePulmonologyIL 13 and AsthmaGene ExpressionAnti-asthmatic AgentBiochemistryPediatricsimmune system diseasesFormoterol FumarateMolecular Cell BiologyAnti-Asthmatic AgentsBudesonideChildCells CulturedMultidisciplinaryImmune System ProteinsQInterleukin-17RFOXP3Forkhead Transcription FactorsNuclear Receptor Subfamily 1 Group F Member 3EthanolaminesMedicineFemaleInterleukin 17medicine.symptommedicine.drugResearch ArticleRhinitis Allergic PerennialAdolescentScienceImmunologyPediatric PulmonologyInflammationAdministration InhalationmedicineHumansAdrenergic beta-2 Receptor AgonistsBiologyAsthmaInflammationbusiness.industryInterleukin-8SputumImmunityProteinsImmunologic Subspecialtiesmedicine.diseaseNasal Lavage FluidAsthmarespiratory tract diseasesCase-Control StudiesImmunologySputumTh17 CellsClinical ImmunologyFormoterolbusinessPulmonary Immunology
researchProduct

Mechanisms in chronic obstructive pulmonary disease: comparisons with asthma

2009

The mechanisms underlying the pathogenesis and pathophysiology of COPD are complex and have been largely studied; however, the underlying factors are not completely understood. Chronic airway inflammation is a key characteristic of COPD and specific inflammatory abnormalities exist even in the airways of subjects with mild and asymptomatic clinical patterns. In addressing these mechanisms, a comparison with asthma becomes fundamental, since the latter shows clinical and functional aspects that overlap with those observed in COPD. The mechanisms of inflammation in COPD, and their similarities and differences with asthma are therefore discussed in this article. The diagnosis of chronic obstru…

COPD AsthmaSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct

Respiratory disease phenotypes in a general population sample: latent transition analysis

2018

Background: Few data are available on the temporal pattern of respiratory disease phenotypes in general population. Aim: To detect longitudinal patterns of disease phenotypes related to risk factors and physician visits. Methods: Pisan general population sample from 2 cross-sectional studies (PI1: 1991-93; PI2: 2009-11; n=1107), questionnaire-based data. Latent transition analysis (LTA) was performed to assess respiratory disease phenotypes at PI1 and PI2, labelled according to disease/symptom occurrence. Possible patterns were persistence, worsening and improvement of the phenotype. Multiple logistic regression models were estimated to assess the association among phenotype patterns, risk …

COPDmedicine.medical_specialtyeducation.field_of_studybusiness.industryPhlegmRespiratory diseasePopulationDiseasemedicine.diseaseLogistic regressionepidemiology asthma copdInternal medicineEpidemiologymedicinemedicine.symptombusinesseducationAsthmaEpidemiology
researchProduct

ASTHMA–COPD OVERLAP SYNDROME (ACOS): PREVALENZA, QUALITÀ DI VITA CORRELATA ALLO STATO DI SALUTE E IMPLICAZIONI PROGNOSTICHE DI UNA NUOVA ENTITÀ NOSOL…

COPD; asthma; chronic obstructive pulmonary disease; overlap syndrome; mortality; older people.COPDolder people.asthmaoverlap syndromemortalitychronic obstructive pulmonary disease
researchProduct